SEATTLE, March 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that the filing of its annual report on Form 10-K for the year ended December 31, 2007 has now been timely completed. This filing is available for review on CTI's Web site at http://www.celltherapeutics.com/ or on the Securities and Exchange Commission's Web site at http://www.sec.gov/.
As required under Nasdaq Marketplace Rule 4350(b)(1)(B), CTI also announced that its independent auditor's report included in the annual report on Form 10-K contains a "going concern" qualification.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: